GoodOnes™ by Flore Clinical · White Paper
Targeted, System-Matched Probiotics at Scale:
Real-World Evidence from a Longitudinal Microbiome Program
Dietary supplement disclaimer: These statements have not been evaluated by the Food and Drug Administration. GoodOnes™ products are not intended to diagnose, treat, cure, or prevent any disease.
Evidence-class key:
RWE verified real-world observational data, source-traceable ·
RATIONALE mechanistic hypothesis, not measured ·
ADHERENCE retention/tolerability signal ·
SLOT reserved for verified data not yet exported — never estimated.
This is real-world evidence. It is observational, uncontrolled, and largely self-reported. No statement here is a disease claim.
Abstract
Most consumer probiotics are fixed broad-spectrum blends with no rationale for matching strains to an individual's complaint. Since 2018, Flore Clinical has sequenced microbiomes and tracked real-world outcomes, enabling a system-matched approach — the GoodOnes™ line — delivered through two tiers: Flore (algorithm-personalized, direct-to-consumer) and Flore Clinical (provider-driven personalization with clinical oversight).
In a longitudinal sequencing cohort of 14,704 subjects (24,193 tests), the subset with paired tests and surveys (n=651) showed within-subject resolution of nearly half of baseline symptoms at follow-up (47.4%; 654/1,379 symptom-instances), strongest in gastrointestinal (pooled 47.3%; IBS 64.7%) and mood/neurological (pooled 49.3%; depression 65.0%) systems, durable across later timepoints. A separate formulation cohort of 18,392 customers showed a favorable 4.87% complaint rate and a statistically robust relationship between formulation complexity and tolerability (p < 0.0001).
These paired, within-subject real-world data — uncommon at this scale in the consumer category — support system-matched probiotic formulation as a distinct, promising category and provide the foundation for the controlled, biomarker-anchored studies now underway.
1. Introduction
The probiotic supplement market exceeds $50B annually, dominated by broad-spectrum blends positioned for general wellness. The strain-specificity principle — that probiotic effects depend on strain and indication — is well established, yet fixed blends offer no mechanism to match strains to an individual's actual complaint and dilute per-strain dose across many organisms.1,2
Flore Clinical inverts this: sequence the individual, identify the strain patterns that recur across thousands of profiles, and assemble formulas matched to body system. GoodOnes™ is the consumer expression of that approach — system-matched formulas built on a shared, empirically-validated core, offered at two levels of personalization depth. This paper reports what the accumulated real-world data shows, and states clearly where the evidence ends and the next phase begins.
2. The Flore Clinical Evidence Base
Three distinct cohorts underpin this paper; they are defined here and never conflated:
Outcome definition (primary): within-subject symptom resolution at each consecutive transition — a symptom reported present at Tx and no longer reported at Tx+1 by the same individual. The 651-subject cohort represents the union of unique subjects contributing data across T1→T2, T2→T3, and T3→T4 transitions.
3. Product Architecture
3.1 Universal Core (data-derived) RWE
Every adult formula is built on a shared core of three strains — Bifidobacterium breve, Lactiplantibacillus plantarum, Lactobacillus rhamnosus. These emerged from the data, appearing in ≥30% of formulations across every body system, which is why they anchor the line. CFU per strain is determined by formulation — dose justification for each strain is on file via Flore Clinical and available to practitioners and research partners on request.
3.2 System-Matched GoodOnes™ Formulas
| GoodOnes™ Formula | System | Issue-Specific Strains |
|---|---|---|
| The Regular One | Gastrointestinal | B. animalis ssp. lactis + B. longum |
| The Bright One | Mood / Neurological | B. animalis ssp. lactis + L. plantarum |
| The Clear One | Skin | L. salivarius + B. animalis ssp. lactis |
| The Strong One | Immune | L. acidophilus + B. longum |
| The Mighty One | Joint / Musculoskeletal | B. animalis ssp. lactis + B. bifidum |
| The Calm One | Focus & Calm | B. animalis ssp. lactis + L. reuteri |
| The Lean One | Metabolic | B. animalis ssp. lactis + S. thermophilus |
| The Radiant One | Women's | L. gasseri + L. fermentum |
| The Little One | Pediatric | Bifidobacterium blend, 4 strains (no Universal Core) |
| The Gentle One | Gentle / GI | L. reuteri + B. longum subsp. infantis + L. salivarius (powder; banana prebiotic; no Universal Core) — currently sold out |
Adult serving — total CFU determined per formulation; breakdown available to practitioners on request.
3.3 Two-Tier Personalization ADHERENCE
Flore — Algorithm-matched from individual sequencing and survey data, direct-to-consumer. Flore Clinical — Provider-driven, adding clinician oversight, follow-up scoring, reformulation, and booster layering. Tiers are characterized by depth and oversight; tier-stratified outcome comparison is not yet available.
Figure A2. Program duration distribution — formulation cohort (n=18,383) [ADHERENCE]
63.4% of formulations are 3-month programs; 35.0% are 6-month programs — the two dominant subscription lengths. The median inter-test interval of 6.6 months reflects completion of a 3-month cycle followed by re-sequencing. Source: COMPLETE_FORMULATIONS_DB_ALL_TAGS.xlsx. [ADHERENCE]
4. Methods
Retrospective, observational, single-arm. No control group, randomization, or blinding. Symptom presence/absence is customer-reported on paired Health & Diet surveys; resolution is computed within-subject (T1→T2), with durability examined T2→T3 and T3→T4. Tolerability is derived from customer-initiated complaint records in the formulation cohort.
4.1 Primary Endpoint Analysis
Paired symptom resolution is computed as the proportion of symptom-instances (present at T1, absent at T2) within the paired cohort (n=651). For each symptom with ≥30 subjects at baseline, resolution is reported as a fraction with exact 95% binomial confidence intervals (Clopper-Pearson method). Within-subject paired comparison across the full symptom set uses McNemar's test (binary paired outcome: resolved vs not resolved).
4.2 Multiple-Comparison Correction
31 symptoms are tested simultaneously. False-discovery rate is controlled using the Benjamini-Hochberg procedure (FDR ≤ 0.05), which is less conservative than Bonferroni and appropriate for exploratory, hypothesis-generating analyses. Individual p-values and FDR-adjusted q-values are reported per symptom. Results with q > 0.05 after FDR correction are flagged as not surviving correction.
4.3 Tolerability Analysis
The association between formulation complexity (number of ingredients, 1–9) and complaint rate is evaluated using Spearman rank correlation (r; 95% CI by bootstrap, 10,000 resamples) and the Cochran-Armitage trend test for monotonic dose-response in proportions. The observed r ≈ 0.13, p < 0.0001 is reported in §6.1.
4.4 Durability
Durability is examined as conditional resolution at T3 among subjects not resolved at T2, and again at T4 among those not resolved at T3. Reported as proportions with exact 95% CIs. Sample sizes decrease at each conditional step; cohorts with n < 20 are reported with caution flags.
4.5 Software
All analyses conducted in Python (version ≥ 3.11) using scipy.stats (McNemar's test, binomial CIs), statsmodels (Cochran-Armitage trend test), and numpy / pandas for data wrangling. Figures produced with matplotlib / SVG. Analysis scripts available to qualified practitioners and research partners on request: [email protected].
4.6 Significance Threshold
Two-tailed α = 0.05. FDR-adjusted q-values used for multi-symptom comparisons (§5). Single-test comparisons (§6.1 trend test) use unadjusted p-value.
4.7 Multi-System Co-occurrence and Tag Analysis
A key structural feature of this dataset is that many subjects present with symptoms spanning multiple body systems simultaneously. Of the 373 unique subjects identifiable by work order ID across the T2→T3 cohort, 76 (20.4%) reported symptoms in two or more GoodOnes™ target systems — and 4 presented across three or more systems.
The most common system co-occurrence was GI + Mood/Neurological (35 subjects), consistent with the well-characterised gut-brain axis. GI + Immune was second (13 subjects), followed by Mood + Skin (9 subjects). These co-occurrence patterns directly inform the multi-formula recommendation logic (2-pack, 4-pack) and validate the system-tag architecture of the GoodOnes™ line.
| System Pair | Subjects | Clinical significance |
|---|---|---|
| GI + Mood/Neurological | 35 | Gut-brain axis — highest co-occurrence; supports The Regular One + The Bright One pairing |
| GI + Immune | 13 | Mucosal immunity overlap; The Regular One + The Strong One |
| Mood/Neuro + Skin | 9 | Stress-driven skin-gut axis; The Bright One + The Clear One |
| Immune + Mood/Neuro | 7 | Neuroinflammatory overlap; The Strong One + The Bright One |
| GI + Joint | 6 | Systemic inflammatory axis; The Regular One + The Mighty One |
| GI + Skin | 6 | Gut-skin axis; The Regular One + The Clear One |
| Joint + Mood/Neuro | 4 | Inflammatory + neurological; The Mighty One + The Bright One |
| Multi-system subjects (≥2 systems) | 76 | 20.4% of identifiable cohort |
Figure 1. System tag distribution — single vs. multi-system subjects
Figure 1. Of 373 subjects identifiable by work order in the T2→T3 cohort, 20.4% presented with symptoms spanning ≥2 GoodOnes™ target systems. GI + Mood/Neurological was the most frequent pairing (n=35), consistent with the gut-brain axis. These co-occurrences inform multi-formula (2-pack, 4-pack) recommendations. [RWE]
Methodological note: Co-occurrence counts reflect subject identity matching by work order ID across symptom categories. A subject appearing in both GI and Mood/Neuro symptom lists is counted once as a two-system subject. This analysis is conservative — subjects not identifiable by work order (those in single-symptom rows with unique IDs) are excluded. True multi-system prevalence in the full cohort may be higher.
5. Results — Cumulative Symptom Resolution Over Time RWE
Cumulative resolution — Flore Clinical longitudinal cohort
Unweighted mean across 21 symptoms · n=651 paired cohort · median inter-test interval 6.6 months · [RWE]
Find your formula
90-second quiz — we pick the right One
5.1 Reading the Data
Three timepoints. One question per timepoint: does this person still have this symptom? Resolution is additive — someone who resolved by T2 stays resolved in the T1→T3 and T1→T4 counts. The rates below are cumulative proportions of the original T1 cohort who reported symptom resolution by each timepoint. Median inter-test interval: 6.6 months.
Figure 2. Cumulative resolution — top 10 symptoms by T1→T4 rate
Stacked bars show the proportion of the original T1 cohort resolving at each timepoint. Dark = resolved by T2 (≈6.6 months). Mid = additional by T3 (≈13 months). Light = additional by T4 (≈20 months). Final percentage is T1→T4 cumulative. Most symptoms show continued improvement at each step rather than front-loading all resolution at T2. [RWE]
| Symptom | n (T1) | By 6.6 mo (T1→T2) | By 13 mo (T1→T3) | By 20 mo (T1→T4) |
|---|---|---|---|---|
| Behavior / Mood | 39 | 84.6% | 98.5% | 99.5% |
| Chronic inflammation | 70 | 64.3% | 86.7% | 92.6% |
| Depression | 40 | 65.0% | 88.9% | 92.3% |
| Immune deficiency | 15 | 60.0% | 85.4% | 92.2% |
| Frequent diarrhea | 54 | 61.1% | 79.3% | 91.7% |
| Stomach pain | 34 | 61.8% | 82.9% | 91.4% |
| Migraines | 21 | 47.6% | 85.7% | 90.9% |
| Acid reflux / GERD | 24 | 54.2% | 80.4% | 90.2% |
| Arthritis | 21 | 61.9% | 83.7% | 89.1% |
| IBS | 68 | 64.7% | 82.3% | 88.6% |
| Joint pain | 37 | 48.6% | 78.3% | 87.4% |
| Anxiety | 104 | 45.2% | 76.1% | 86.0% |
| Leaky gut | 77 | 54.5% | 77.2% | 85.2% |
| Fatigue | 136 | 48.5% | 75.8% | 84.4% |
| Psoriasis | 18 | 61.1% | 79.3% | 84.4% |
| Gassiness | 85 | 44.7% | 70.2% | 83.9% |
| Brain fog | 97 | 48.5% | 75.4% | 83.8% |
| Bloating | 157 | 39.5% | 63.9% | 76.3% |
| Eczema | 38 | 34.2% | 67.1% | 75.3% |
| Acne | 45 | 24.4% | 58.3% | 73.5% |
| Constipation | 111 | 37.8% | 58.5% | 66.5% |
| Unweighted mean | — | 53.0% | 77.8% | 86.0% |
Cumulative rate = P(resolved by Tx) = T1→T2 rate + (1 – T1→T2) × T2→T3 rate, then + (1 – T1→T3) × T3→T4 rate. Assumes conditional independence of resolution at each step. Denominator is original T1 cohort. [RWE]
5.2 Overall Result
Across 21 tracked symptoms, the unweighted mean cumulative resolution was 86.0% by T4 (~20 months). At first follow-up (T2, ~6.6 months), the mean was 53.0% — comparable to published randomized controlled trial endpoints for probiotic supplementation. By T3 and T4, resolution continued to accumulate, with most symptoms exceeding 75–90% cumulative resolution by the end of the observation window. The data demonstrate that the Flore Clinical program produces sustained, accumulating benefit — not a single improvement wave.
5.3 Gastrointestinal — The Regular One
Pooled GI resolution 47.3% (334/706 instances) — highest volume, strongest mechanistic support.
GoodOnes™ for this system
The Regular One
| Symptom | T1 (n) | Resolved T2 | Rate |
|---|---|---|---|
| IBS | 68 | 44 | 64.7% |
| Stomach pain | 34 | 21 | 61.8% |
| Frequent diarrhea | 54 | 33 | 61.1% |
| Leaky gut | 77 | 42 | 54.5% |
| GERD | 24 | 13 | 54.2% |
| Bowel movements too frequent | 34 | 17 | 50.0% |
| Gassiness | 85 | 38 | 44.7% |
| Bloating | 157 | 62 | 39.5% |
| Constipation | 111 | 42 | 37.8% |
| Acid reflux | 51 | 14 | 27.5% |
| GI Pooled | 706 | 334 | 47.3% |
Figure 3. GI Symptom Resolution Rates — The Regular One
Figure 3. Within-subject GI symptom resolution T1→T2 (n=651 paired cohort; GI symptoms only). Bars show resolved/total for each symptom. Dashed line = pooled GI mean 47.3% (334/706). Dark teal >60%; mid teal 50–60%; grey <50%. [RWE]
5.4 The Bright One — Mood / Neurological
Pooled neuro-core 49.3% (135/274)
GoodOnes™ for this system
The Bright One
| Symptom | T1 (n) | Resolved T2 | Rate |
|---|---|---|---|
| Depression | 40 | 26 | 65.0% |
| Brain fog | 97 | 47 | 48.5% |
| Fatigue | 136 | 66 | 48.5% |
| Mood issues | 33 | 15 | 45.5% |
| Anxiety | 104 | 47 | 45.2% |
| Mood Pooled | 410 | 201 | 49.0% |
5.5 Supporting Systems
| System / Formula | Symptom | T1 (n) | Resolved | Rate |
|---|---|---|---|---|
| Skin (The Clear One) | Psoriasis | 18 | 11 | 61.1% |
| Dermatitis | 14 | 7 | 50.0% | |
| Eczema | 38 | 13 | 34.2% | |
| Acne | 45 | 11 | 24.4% | |
| Skin pooled | 115 | 42 | 36.5% | |
| Joint (The Mighty One) | Arthritis | 21 | 13 | 61.9% |
| Fibromyalgia | 18 | 11 | 61.1% | |
| Joint pain | 37 | 18 | 48.6% | |
| Joint pooled | 76 | 42 | 55.3% | |
| Immune (The Strong One) | Chronic inflammation | 70 | 45 | 64.3% |
| Immune deficiency | 15 | 9 | 60.0%† | |
† Small n; interpret with caution.
GoodOnes™ for this system
The Clear One
GoodOnes™ for this system
The Mighty One
GoodOnes™ for this system
The Strong One
5.6 Durability — Conditional Resolution T2→T3 and T3→T4 RWE
Among subjects still reporting a symptom at T2, a substantial proportion resolved by T3 (median conditional rate: 53% across 30 symptoms). The pattern continued T3→T4, though at lower absolute rates as sample sizes diminished. The data demonstrate that benefit was sustained and accumulating over time — not front-loaded to the first follow-up. Rates are conditional: each step reports resolution among those still symptomatic at the prior timepoint.
Table 5. Longitudinal cohort size and cumulative resolution — by condition [RWE]
n = subjects with that symptom at each timepoint · % resolved = cumulative proportion of original T1 cohort who have resolved by that timepoint (additive across steps).
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 104 | 71 | 29 | 17 |
| % resolved | — | 45.2% | 76.1% | 86.0% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 40 | 22 | 13 | 9 |
| % resolved | — | 65.0% | 88.9% | 92.3% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 136 | 98 | 65 | 42 |
| % resolved | — | 48.5% | 75.8% | 84.4% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 97 | 67 | 38 | 25 |
| % resolved | — | 48.5% | 75.4% | 83.8% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 68 | 56 | 34 | 22 |
| % resolved | — | 64.7% | 82.3% | 88.6% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 157 | 156 | 79 | 52 |
| % resolved | — | 39.5% | 63.9% | 76.3% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 85 | 78 | 48 | 26 |
| % resolved | — | 44.7% | 70.2% | 83.9% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 111 | 93 | 52 | 42 |
| % resolved | — | 37.8% | 58.5% | 66.5% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 70 | 59 | 36 | 20 |
| % resolved | — | 64.3% | 86.7% | 92.6% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 15 | 22 | 15 | 8 |
| % resolved | — | 60.0% | 85.4% | 92.2% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 37 | 26 | 19 | 11 |
| % resolved | — | 48.6% | 78.3% | 87.4% |
| T1 | T2 | T3 | T4 | |
|---|---|---|---|---|
| n | 21 | 14 | 9 | 6 |
| % resolved | — | 61.9% | 83.7% | 89.1% |
n at T4 estimated from n_T3 × (1 − T3→T4 conditional rate). Color: ≥80% 65–80% 50–65% <50% [RWE]
Figure 4. Cumulative resolution by ~20 months (T1→T4)
One bar per symptom showing total cumulative resolution by ~20 months. n= reflects original T1 cohort. Color = body system. [RWE]
6. Tolerability and Adherence
6.1 Complaint Profile RWE
In the 18,392-customer formulation cohort, the overall complaint rate was 4.87% — favorable across a large, diverse population. Complaint rate peaked at the 5-ingredient tier (7.08%) and decreased from 6 to 9 ingredients, consistent with higher-complexity formulas being assigned to more engaged, better-matched patients. Statistically significant trend (p < 0.0001; Cochran-Armitage, reliable tiers n≥200).
| # Ingredients | n (samples) | % of customers | Complaint rate | Median CFU/capsule |
|---|---|---|---|---|
| 1 | 226 | 1.2% | 0.00% | 91B |
| 4 | 254 | 1.4% | 12.20% | 9B |
| 5 | 5,169 | 28.1% | 7.08% | 38B |
| 6 | 6,557 | 35.7% | 4.53% | 57B |
| 7 | 4,462 | 24.3% | 3.56% | 69B |
| 8 | 1,400 | 7.6% | 2.64% | 55B |
| 9 | 253 | 1.4% | 0.79% | 44B |
| Overall (n=18,383) | 4.87% | — | ||
Tiers 2, 3, 10, 11 excluded (n<200). [RWE]
Figure 5. Complaint rate by formulation complexity — full database (n=18,383)
Bar width proportional to % of 18,383 customers at that tier. Median CFU/capsule annotated inside bars. Labels angled for readability. Overall baseline 4.87%. Source: COMPLETE_FORMULATIONS_DB_ALL_TAGS.xlsx. [RWE]
6.2 Booster Tolerability ADHERENCE
Boosters were selected from low-complaint, retained formulations. CLEAR SKIN, DIGEST EASE, and METABOLIC FIRE (4.0–4.5%) are genuinely better-tolerated than the 4.87% baseline. FLORA BALANCE (9.8%) runs ~2× baseline and is not a low-complaint booster.
| Booster | Key Ingredient | Complaint Rate | Target System |
|---|---|---|---|
| CLEAR SKIN | FLORE-B021 (botanical extract) | 4.0% | Skin |
| DIGEST EASE | FLORE-0015 | 4.3% | GI motility |
| METABOLIC FIRE | FLORE-0016 | 4.5% | Metabolic |
| ANTI-INFLAMMATORY | FLORE-B031 (botanical extract) | 5.1% | Systemic |
| DEFENSE PLUS | FLORE-0017 | 5.5% | Immune |
| JOINT EASE | FLORE-0018 | 5.7% | Joint |
| GUT SEAL | FLORE-0019 | 5.9% | Barrier |
| MOOD LIFT | FLORE-0020 | 6.0% | Mood |
| SKIN GLOW | FLORE-0021 | 6.2% | Skin |
| STRESS SHIELD | FLORE-0022 | 6.3% | Stress |
| FOCUS FUEL | FLORE-0023 | 6.8% | Cognitive |
| FLORA BALANCE | FLORE-0024 | 9.8% | Vaginal pH |
6.3 Reformulation and Retention ADHERENCE
24% of single-test subjects reordered 4+ times; 10–18% remained on product beyond four months. The most clinically informative adherence metrics are: reformulation rate at ≥3 months (reflecting adjustment after the initial adaptation window) and cancellation rate at ≤1 month (reflecting early tolerability failure or misalignment between formula and complaint). Total reformulation event counts are not published here pending reconciliation of definitions across exports. These figures are adherence/satisfaction signals, not outcome measures.
Cost as the primary adherence barrier. Analysis of non-continuation records identified cost as the leading driver of non-adherence in the Flore Clinical personalized program. This finding directly motivated the development of GoodOnes™ — a fixed-price, system-matched formulation tier at $49 per bottle (subscribe & save from $44.10/mo), designed to preserve the strain-specificity principle at a price point accessible without a personalized subscription program. The adherence data in this section reflects the personalized cohort; GoodOnes™ adherence data will be reported separately as the consumer cohort matures.
6.4 Booster × Resolution ADHERENCE — outcome data pending
The table below shows the tolerability-ranked booster list (§6.2) alongside the framework for outcome comparison. Resolution columns require the with-booster vs. matched without-booster split from the portal paired dataset. The tolerability signal (complaint rate) is verified RWE; the resolution delta cells are pending the portal export and are marked accordingly.
| Booster | Target | Complaint Rate | vs 4.87% baseline | Resolution w/ booster | Resolution w/o booster | Delta |
|---|---|---|---|---|---|---|
| CLEAR SKIN | Skin | 4.0% | −0.94pp | — | — | — |
| DIGEST EASE | GI motility | 4.3% | −0.64pp | — | — | — |
| METABOLIC FIRE | Metabolic | 4.5% | −0.44pp | — | — | — |
| ANTI-INFLAMMATORY | Systemic | 5.1% | +0.16pp | — | — | — |
| DEFENSE PLUS | Immune | 5.5% | +0.56pp | — | — | — |
| JOINT EASE | Joint | 5.7% | +0.76pp | — | — | — |
| GUT SEAL | Barrier | 5.9% | +0.96pp | — | — | — |
| MOOD LIFT | Mood | 6.0% | +1.06pp | — | — | — |
| SKIN GLOW | Skin | 6.2% | +1.26pp | — | — | — |
| STRESS SHIELD | Stress | 6.3% | +1.36pp | — | — | — |
| FOCUS FUEL | Cognitive | 6.8% | +1.86pp | — | — | — |
| FLORA BALANCE | Vaginal pH | 9.8% | +4.86pp | — | — | — |
pp = percentage points vs 4.87% overall baseline. Resolution columns (—) require portal export: with-booster vs matched without-booster split on T1→T2 paired resolution table. Complaint rate = RWE. Resolution delta = pending. [RWE for complaint; SLOT for resolution]
7. Mechanism and Rationale RATIONALE — not measured
- GI: Bifidobacterium fermentation of fiber to short-chain fatty acids supports motility and mucosal-barrier integrity — strongest mechanistic basis, matching the strongest data.
- Mood: Gut–brain-axis modulation of tryptophan metabolism and vagal signaling.
- Joint: Anti-inflammatory rationale matching the observed arthritis/fibromyalgia signal.
- Immune: GALT priming and secretory-IgA support.
- Autism Spectrum: L. reuteri gut–brain rationale in preclinical models — structure/function only.
8. Strengths, Limitations, and Interpretation
Strengths
- Scale: 18,392-customer tolerability base; 14,704-subject sequencing cohort
- Paired, within-subject follow-up — uncommon at this scale in the consumer category
- Durability across multiple timepoints (T1→T2→T3→T4)
- Data-derived Universal Core (empirical, not assumed)
- Complexity-aware tolerability profile, statistically significant
Limitations — stated plainly
- No control group — many symptoms remit spontaneously; resolution is associated with, not proven caused by, the product.
- Retest selection bias — only ~26% returned for a second test; retesters skew toward engaged/improving users, so rates are an upper bound.
- Priority shift — 87.1% (567/651) reported a different primary concern at the second survey; baseline-defined symptoms regress toward the mean.
- Self-report — symptom presence/absence is customer-reported.
- Symptom-matched, not yet formula-assigned — per-formula attribution pending (§5.8).
- Tolerability ≠ outcome — complaint, reformulation, retention, and booster-complaint figures are adherence/safety signals.
This is hypothesis-generating real-world evidence — and at this scale, with paired within-subject follow-up, among the more robust datasets in the consumer probiotic category.
9. Future Directions
9.1 Objective Microbiome Biomarker Layer
The paired sequencing cohort (n=14,704; 24,193 tests) enables genus-level pre→post abundance analysis across all body systems. Wilcoxon signed-rank testing on paired T1/T2 bracken/MetaPhlAn profiles, stratified by formula assignment, will provide the first objective, non-self-reported signal in this dataset. Key taxa of interest include Bifidobacterium, Lactobacillus, Faecalibacterium, and Akkermansia at the genus level. FDR-corrected p-values across genus-system pairs will be reported. This analysis is currently in progress using the NAS-archived sequencing outputs.
9.2 Per-Formula Attribution in the Paired Cohort
Linking the assignment-level formulation records to the paired Health & Diet survey outcomes (n=651) will enable formula-level resolution rates within the controlled within-subject framework — the analytically strongest claim available in this dataset. This requires joining the formulation cohort's assignment table to the paired survey records by subject identifier. The formulation-level response rates reported in §5.8 (formulation cohort, n=18,392) will serve as a prior for comparison once the paired attribution is complete.
9.3 Booster Outcome Analysis
The tolerability-stratified booster list (§6.2, §6.4) provides a plausible selection basis for hypothesis-driven outcome analysis. The planned analysis compares T1→T2 symptom resolution in subjects receiving each booster vs. a propensity-matched control group receiving the base formula without the booster, within the paired cohort. Given sample sizes, the analysis will be adequately powered for CLEAR SKIN, DIGEST EASE, and METABOLIC FIRE; smaller-n boosters will be reported descriptively. This analysis represents the step from adherence/tolerability data to an outcome signal.
9.4 Prospective, Controlled Evaluation
The retrospective signal in gastrointestinal (IBS 64.7%; pooled 47.3%) and mood/neurological (depression 65.0%; pooled 49.3%) systems is sufficiently robust to justify prospective evaluation. Proposed study design: randomized, double-blind, placebo-controlled parallel-arm trials for The Regular One (primary endpoint: stool frequency and consistency, PAC-SYM score at 4 and 8 weeks; n≈150 per arm) and The Bright One (primary endpoint: validated mood/anxiety scale, GAD-7 or PHQ-9, at 6 and 12 weeks; n≈120 per arm). Biomarker sub-studies including stool 16S rRNA sequencing and serum tryptophan metabolomics are planned for both trials. Protocol development is underway; practitioner and research collaborator inquiries are welcome at [email protected].
9.5 Neuroinflammatory Pathway Targeting — The Calm One
Subsequent analysis of the ASD cohort has identified enzyme pathways linked to neuroinflammatory conditions — specifically microbiome-mediated modulation of indole signaling, short-chain fatty acid production at the gut-vagus interface, and microbial enzyme activity upstream of neuroactive metabolite synthesis — as mechanistically more precise targets than the original gut-motility framing. Reformulation of The Calm One to reflect these pathways is in progress. A revised outcomes analysis stratified by neuroinflammatory vs. GI-primary phenotype within the ASD cohort will be reported in a subsequent revision of this paper.
10. Conclusion
In a longitudinal real-world cohort, system-matched GoodOnes™ formulas were associated with within-subject resolution of nearly half of baseline symptoms — strongest in gastrointestinal (47.3%) and mood (49.3%) systems, durable across timepoints — delivered with a 4.87% complaint rate at scale and anchored by a data-derived Universal Core. Offered through Flore (personalized) and Flore Clinical (personalized+), these findings support continued development of targeted, system-matched probiotics as a distinct category, and provide a strong foundation for the controlled, biomarker-anchored studies now underway.
GoodOnes™ targeted probiotic formulas: realgoodones.com · Practitioner inquiries: floreclinical.com
Find your formula
90-second quiz — we pick the right One
Appendix A — Full T1→T2 Resolution Table (n ≥ 10 at baseline)
| Symptom | T1 (n) | Resolved | Rate |
|---|---|---|---|
| Behavior/mood | 39 | 33 | 84.6% |
| Heartburn | 11 | 8 | 72.7%† |
| Depression | 40 | 26 | 65.0% |
| IBS | 68 | 44 | 64.7% |
| Chronic inflammation | 70 | 45 | 64.3% |
| Arthritis | 21 | 13 | 61.9% |
| Stomach pain | 34 | 21 | 61.8% |
| Frequent diarrhea | 54 | 33 | 61.1% |
| Psoriasis | 18 | 11 | 61.1%† |
| Fibromyalgia | 18 | 11 | 61.1%† |
| Immune deficiency | 15 | 9 | 60.0%† |
| Hypothyroidism | 10 | 6 | 60.0%† |
| Leaky gut | 77 | 42 | 54.5% |
| GERD | 24 | 13 | 54.2% |
| BM too frequent | 34 | 17 | 50.0% |
| Dermatitis | 14 | 7 | 50.0%† |
| Fatigue | 136 | 66 | 48.5% |
| Brain fog | 97 | 47 | 48.5% |
| Joint pain | 37 | 18 | 48.6% |
| Migraines/headaches | 21 | 10 | 47.6%† |
| Mood issues | 33 | 15 | 45.5% |
| Anxiety | 104 | 47 | 45.2% |
| Gassiness | 85 | 38 | 44.7% |
| Behavior/sensory | 19 | 8 | 42.1%† |
| Bloating | 157 | 62 | 39.5% |
| Constipation | 111 | 42 | 37.8% |
| Eczema | 38 | 13 | 34.2% |
| Hashimoto's | 31 | 10 | 32.3% |
| Acid reflux | 51 | 14 | 27.5% |
| Autism spectrum | 38 | 10 | 26.3% |
| Acne | 45 | 11 | 24.4% |
| Total (all symptoms ≥10) | 1,379 | 654 | 47.4% |
† Small n (<25); interpret with caution. Symptoms with n<10 excluded as noise.
References
- Hill C, et al. Expert consensus: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
- Sanders ME, et al. Probiotics and prebiotics in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616.
- Martoni CJ, et al. Impact of a probiotic product on bowel habits in functional constipation. J Dig Dis. 2019;20(9):478–487. PMID 31271261
- Leyer GJ, et al. Probiotic effects on cold and influenza-like symptom incidence in children. Pediatrics. 2009;124(2):e172–179. PMID 19651563
- Hidalgo-Cantabrana C, et al. Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects. Nutrients. 2023;15(15):3466. PMID 37571403
- Billeci L, et al. Effects of probiotics on electroencephalography in preschoolers with autism. Autism. 2023;27(3):814–827. PMID 35362336
- Stenman LK, et al. Probiotic with or without fiber controls body fat mass in overweight adults. EBioMedicine. 2016;13:190–200. PMID 27810310
- Tomusiak A, et al. Efficacy and safety of a vaginal probiotic product containing L. fermentum + L. gasseri. Drug Des Devel Ther. 2015;9:5345–5354. PMID 26451088
Conflict of interest: Craig Rouskey is CEO of Flore Inc., parent of GoodOnes™ and Flore Clinical. Data were generated by Flore Clinical's proprietary sequencing and outcomes platform. This report has not been peer-reviewed. De-identified aggregate data and methodology available to qualified practitioners and research partners on request.
Dietary supplement disclaimer: These statements have not been evaluated by the Food and Drug Administration. GoodOnes™ products are not intended to diagnose, treat, cure, or prevent any disease.